Pacer Advisors Inc. Has $55.74 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Pacer Advisors Inc. lessened its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 5.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,804,013 shares of the biopharmaceutical company’s stock after selling 163,562 shares during the quarter. Pacer Advisors Inc. owned 2.35% of Catalyst Pharmaceuticals worth $55,744,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Catalyst Pharmaceuticals by 12.1% during the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after purchasing an additional 860,244 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Catalyst Pharmaceuticals by 9.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock worth $46,479,000 after acquiring an additional 263,099 shares during the period. Janus Henderson Group PLC lifted its position in Catalyst Pharmaceuticals by 139.5% during the first quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock valued at $43,445,000 after buying an additional 1,587,794 shares during the period. Renaissance Technologies LLC lifted its position in Catalyst Pharmaceuticals by 15.2% during the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock valued at $33,702,000 after buying an additional 287,300 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Catalyst Pharmaceuticals by 1.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,219,418 shares of the biopharmaceutical company’s stock worth $19,439,000 after purchasing an additional 22,860 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on CPRX. Stephens initiated coverage on Catalyst Pharmaceuticals in a research report on Monday. They issued an “overweight” rating and a $35.00 target price for the company. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Citigroup upped their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Truist Financial increased their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $31.14.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $21.12 on Friday. Catalyst Pharmaceuticals, Inc. has a one year low of $13.00 and a one year high of $24.27. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of 17.90, a PEG ratio of 3.29 and a beta of 0.75. The stock has a 50 day moving average price of $21.09 and a 200 day moving average price of $18.47.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.